Human Growth Hormone Fragment 176-191 (HGH Frag 176-191) is a synthetic peptide sequence representing amino acids 176–191 of the full human growth hormone (HGH) molecule. This region has been studied for its potential influence on fat metabolism, energy regulation, and cellular signaling—independent of the full anabolic profile of unmodified HGH.

In research settings, HGH Frag 176-191 has demonstrated an ability to mimic the lipolytic (fat-mobilizing) activity of natural HGH without measurable effects on insulin sensitivity or cell proliferation. Its molecular design isolates the metabolic signaling region responsible for modulating lipid turnover, making it a focused subject in metabolic and anti-aging research.

Research Overview

• Comprises the final 16 amino acids (176–191) of the human growth hormone chain.
• Explored for selective interaction with receptors involved in lipid oxidation and metabolic control.
• Early laboratory data suggest approximately 10–12× higher lipolytic activity than full-length HGH in some model systems.
• Does not exhibit measurable mitogenic (cell growth) effects typical of native GH.

Scientific Background

Investigators at Monash University identified that the fat-reducing properties of HGH originate from this terminal peptide region. This discovery led to development of HGH 176-191 analogues that emulate growth hormone’s fat-regulatory effects—stimulating lipolysis (fat breakdown) and suppressing lipogenesis (fat formation)—without influencing insulin response or somatic growth.

Product Composition

• Compound: Human Growth Hormone Fragment 176-191 (HGH Frag 176-191)
• Form: Lyophilized peptide powder
• Purity: ≥98% (HPLC verified)
• Content: 2500 mcg (2.5 mg) per vial

Kit Contents

• 4 × 2500 mcg vials of HGH Frag 176-191
• 4 × 1.2 mL vials of sterile bacteriostatic water
• 4 × 1 mL insulin syringes (for laboratory measurement and reconstitution handling)

Laboratory Reconstitution Reference

Add 1 mL of bacteriostatic water per vial. Introduce the liquid slowly along the glass wall and swirl gently until dissolved. Label each vial with concentration and preparation date.

• 1 mL reconstitution yields a reference concentration of 2500 mcg/mL.
• Handle under sterile laboratory conditions; avoid vigorous shaking.
• Store at 2–8 °C after reconstitution and use within 30 days.

Research Focus Areas

• Lipid metabolism and energy regulation models
• GH-fragment receptor pathway exploration
• Endocrine balance and anti-aging biochemical research
• Comparative peptide analysis alongside full-length HGH

Storage & Stability

• Lyophilized powder: Store at −20 °C in a light-protected environment
• Reconstituted form: Refrigerate at 2–8 °C; avoid repeated freeze–thaw cycles

Why Choose EU Pharmaceuticals?

EU Pharmaceuticals provides research-grade peptides manufactured under strict quality controls. Each batch is tested for identity, purity, and consistency using validated HPLC and mass-spectrometry methods. Packaging is batch-coded for traceability and transparent laboratory compliance.

For laboratory, educational, and research use only. Not intended for human or veterinary administration, diagnostic, or therapeutic use. No weight-loss, medical, or cosmetic claims are made or implied. Buyer is responsible for lawful handling, storage, and compliance with applicable regulations.